Injection of new medicine into facial joint to relieve joint pain and compare with another medication.
Not Applicable
Completed
- Registration Number
- CTRI/2021/10/037043
- Lead Sponsor
- Dr Chandini Ravikumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Healthy patients aged 20-50 years, diagnosed with TMJ internal derangement according to Wilkes classification (stage 2-4), and who are not under NSAIDs medication are included in the study.
Exclusion Criteria
Patients with rheumatic disease, any surgical intervention of the TMJ, infection, diabetes, severe cardiovascular disease, coagulopathy, anticoagulant therapy and pregnancy are excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical parameters assessed are TMJ pain, clicking sounds, mouth opening, jaw deviation, functional limitation and masticatory efficiency. A positive outcome, with 90% improvement in clinical condition would be expected in this prospective study.Timepoint: The parameters are assessed pre-operatively, post-operatively immediate, 2 weeks, 1 month and 2 months.
- Secondary Outcome Measures
Name Time Method Radiological parameters to be assessed are joint effusion, disc displacement, disc non-recapture, disc degenerative changes, abnormal condyle translation and condyle arthritis.Timepoint: MRI parameters are assessed using TMJ internal derangement score (TIDS score 0 to 12). MRI will be taken pre-operatively and post-operatively after 2 months.